TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33544337
Drug: Comparator EGFR
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator EGFR TKI (gefitinib 250 mg once daily or erlotinib)
Study: 33275096
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin alone
Study: 33275096
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin plus graduated compression stockings
Study: 36990261
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation (OAC) treatment
Study: 32053630
Drug: Moderate NPK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate NPK treatment (50 kg N + 10 kg P + 50 kg K /ha)
Study: 32053630
Drug: High NPK
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High NPK treatment (100 kg N + 25 kg P + 100 kg K /ha)
Study: 32053630
Drug: Potassium only
Normalized name: Potassium only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium only treatment (50 kg K/ha)
Study: 35776034
Drug: Quercetin-containing supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin-containing supplement (200 mg daily for 4 weeks)
Study: 35383823
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (16,800 IU vitamin D3 once a week for 1 year) in subgroup with 25(OH)D concentrations of 15-25 nmol/L (n=31)
Study: 35383823
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in subgroup with 25(OH)D concentrations of 15-25 nmol/L (n=31)
Study: 34956849
Drug: Structured education
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured education on TB-DM combined with clinical monitoring and medication adjustment
Study: 32378932
Drug: Online intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online intervention for alcohol use and PTSD (details on dosage and duration not available)
Study: 36397390
Drug: Midazolam 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.06 mg/kg (M2)
Study: 32565073
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg doxycycline
Study: 33356547
Drug: Deterra Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deterra Drug Deactivation System deactivation pouches
Study: 33499754
Drug: modified directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified directly administered antiretroviral therapy (mDAART)
Study: 34673536
Drug: Self-administered high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered high-intensity interval training guided by smartphone app (AG)
Study: 34766589
Drug: 2000 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU/day of oral cholecalciferol (vitamin D)
Study: 32841433
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg pycnogenol taken orally twice a day for 60 days
Study: 32841433
Drug: Placebo taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken orally twice a day for 60 days
Study: 616769481
Drug: Lidocaine 20
Normalized name: lidocaine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 20 mg IV
Study: 616769481
Drug: Lidocaine 20
Normalized name: lidocaine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 20 mg and Ketorolac 10 mg IV
Study: 35738656
Drug: HMB-enriched nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB-enriched nutritional supplements (65 g/day)
Study: 32211776
Drug: Negative HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative HBV RNA and HBcrAg < 4 log10 U/mL at end of treatment (EOT)
Study: 32211776
Drug: Positive HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive HBV RNA and HBcrAg ≥ 4 log10 U/mL at EOT
Study: 32211776
Drug: Negative HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative HBV RNA and HBcrAg < 4 log10 U/mL at EOT
Study: 32211776
Drug: Entecavir or
Normalized name: entecavir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir or tenofovir before discontinuation (validation cohort)
Study: 33991482
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all information
Study: 36382987
Drug: Tazarotene 0.045%
Normalized name: TAZAROTENE 0.045% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.045% lotion
Study: 33683083
Drug: Vehicle lotion
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle lotion
Study: 34624047
Drug: Lifestyle medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle medicine group (LM group)
Study: 32344285
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone administration (levothyroxine and liothyronine)
Study: 35312970
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with luseogliflozin 2.5 mg once daily and semaglutide 0.5 mg once per week
Study: 35312970
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with semaglutide
Study: 32826450
Drug: Thin-strut drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thin-strut drug-eluting stent (DES)
Study: 32826450
Drug: Thick-strut drug-eluting
Normalized name: tick-borne encephalitis purified antigen Prefilled Syringe [Ticovac]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thick-strut drug-eluting stent (DES)
Study: 33225901
Drug: FDA-approved immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA-approved immune checkpoint inhibitors (ICIs)
Study: 35714551
Drug: Methylphenidate (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (continued treatment for 7 weeks)
Study: 34929355
Drug: Wii therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wii therapy (interactive gaming, Nintendo Wii)
Study: 32572617
Drug: EX +
Normalized name: Freeflex + Transfer Adapter
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX + PRO (30 min low-moderate-intensity treadmill walking followed by 20 g whey protein)
Study: 33433386
Drug: FA-TiO2-Pc (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: FA-TiO2-Pc (low dose)
Study: 35236735
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg olanzapine (OLZ) in combination with triple antiemetic therapy
Study: 35236735
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with triple antiemetic therapy
Study: 32202716
Drug: Xiao's 'xingnaofusu'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiao's 'xingnaofusu' needling and routine western medicine
Study: 35911085
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) <1 year after diagnosis
Study: 32975189
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream (Aldara) for up to 16 weeks
Study: 32975189
Drug: 0.15% podophyllotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% podophyllotoxin cream (Warticon) for 4 weeks (extended to 16 weeks if warts persisted)
Study: 32975189
Drug: Quadrivalent human
Normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent human papillomavirus vaccine (Gardasil)
Study: 32975189
Drug: Saline control
Normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline control (placebo for HPV vaccine)
Study: 32975189
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream (Aldara)
Study: 32975189
Drug: 0.15% podophyllotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% podophyllotoxin cream (Warticon)
Study: 32882244
Drug: Balanced crystalloids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced crystalloids (lactated Ringer's solution or Plasma‐Lyte A)
Study: 36178015
Drug: Multifaceted optimization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted optimization management (integration of usual care and traditional Chinese medicine treatment)
Study: 34990772
Drug: L-Citrulline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Citrulline (6 g/day)
Study: 34878335
Drug: Flow cytometry-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow cytometry-based antibiotic susceptibility testing (MICy)
Study: 35383975
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (Lactobacillus and Bifidobacterium spp)
Study: 35383975
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole (MET)
Study: 32694215
Drug: Albiglutide +
Normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albiglutide + optimized basal insulin glargine and lispro (dose reduced by 50% at randomization; lispro injections fully discontinued 4 weeks later)
Study: 34764501
Drug: Isobaric levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric levobupivacaine (0.5%, 0.3-0.4 mg/kg)
Study: 34764501
Drug: Isobaric ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric ropivacaine (0.5%, 0.5 mg/kg)
Study: 34106357
Drug: Robot-assisted Pivotal
Normalized name: PIVOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted Pivotal Response Treatment (PRT + robot)
Study: 33069784
Drug: Endothelial function
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelial function guided treatment group
Study: 33872825
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOACs) prescribed by PCPs
Study: 34191028
Drug: Daily meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily meal with 1 fresh Hass avocado
Study: 32871530
Drug: High-intensity light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity light therapy (LT-5000 lux)
Study: 32871530
Drug: Low-intensity light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity light therapy (LT-500 lux)
Study: 35954937
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline solution (placebo)
Study: 34268638
Drug: Slowness therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slowness therapy (weekly speech therapy sessions with stimuli played slowly on a PC)
Study: 34268638
Drug: Real-time stimuli
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time stimuli speech therapy (age- and level-matched control group)
Study: 34111616
Drug: Manipulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulation of gut bacteria (via FMT or antibiotics)
Study: 36102337
Drug: Cocoa extract
Normalized name: Cocoa extract
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa extract (500 mg/day flavanols)
Study: 33159574
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (menaquinone-7) 180 µg twice a day for 12 weeks
Study: 33228575
Drug: Aripiprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15 mg orally)
Study: 33228575
Drug: Aripiprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15 mg orally) with abnormally low prolactin levels
Study: 33228575
Drug: Aripiprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15 mg orally) without abnormally low prolactin levels
Study: 32302504
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 (5 μg/day for 100 days)
Study: 32302504
Drug: Standard supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard supplementation (350 mg/day ferrous iron, 5 mg folic acid)
Study: 33064182
Drug: Metformin (1700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1700 mg daily)
Study: 33189805
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of airway strategies
Study: 33189370
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D - 30 mL of 0.5% levobupivacaine with vasoconstrictor and 6 mg (1.5 mL) of dexamethasone
Study: 33189370
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C - 30 mL of 0.5% levobupivacaine with vasoconstrictor and 1.5 mL of 0.9% saline
Study: 33172907
Drug: Medication-related problems
Normalized name: Psoriasin Problem Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-related problems
Study: 33727522
Drug: 0.075 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg/kg oxycodone (Group A)
Study: 33727522
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg oxycodone (Group B)
Study: 33727522
Drug: 0.125 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg/kg oxycodone (Group C)
Study: 33727522
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and 0.075 mg/kg oxycodone (Group A)
Study: 33727522
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and 0.1 mg/kg oxycodone (Group B)
Study: 33727522
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and 0.125 mg/kg oxycodone (Group C)
Study: 35636580
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (Phase 1)
Study: 32064596
Drug: Topical calcitriol
Normalized name: calcitriol Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcitriol 0.0003%
Study: 32064596
Drug: Topical rapamycin-calcitriol
Normalized name: calcitriol Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rapamycin-calcitriol combination
Study: 35294537
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg orally twice daily for 10 days
Study: 34298398
Drug: ω-3 polyunsaturated
Normalized name: OMEGA-3 POLYUNSATURATES
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 polyunsaturated fatty acid treatment
Study: 32502876
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1.8 mg/kg once every 3 weeks; ≤16 cycles)
Study: 37150125
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules (Bifidobacterium bifidum BGN4 and Bifidobacterium longum BORI)
Study: 33068425
Drug: Hydroxychloroquine once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine once-weekly (400 mg)
Study: 33068425
Drug: Hydroxychloroquine twice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine twice-weekly (400 mg)
Study: 32525564
Drug: High-intensity interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity interval training (HIIT) during cisplatin-based chemotherapy (CBCT) for testicular cancer (TC). The intervention included two weekly HIIT sessions, each with 2 to 4 intervals of 2 to 4 minutes at 85% to 95% of peak heart rate for 9 to 12 weeks.
Study: 34152632
Drug: Hemoadsorption (HA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoadsorption (HA) therapy
Study: 35713873
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 U/mL (Gla-300)
Study: 32243043
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec 100 U/mL (IDeg-100)
Study: 36263928
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 U/mL (Gla-300) and Insulin degludec 100 U/mL (IDeg-100)
Study: 33278503
Drug: Low-dose whole-lung
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose whole-lung irradiation (LD-WLI) 0.5 Gy
Study: 33278503
Drug: Low-dose whole-lung
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose whole-lung irradiation (LD-WLI) 1.0 Gy
Study: 33278503
Drug: Low-dose whole-lung
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose whole-lung irradiation (LD-WLI) overall
Study: 39669005
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injections
Study: 33465795
Drug: Melissa Officinalis
Normalized name: melissa officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melissa Officinalis L. (500 mg daily)
Study: 36121830
Drug: Systematic medication
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic medication review conducted by pharmacists during the emergency department stay
Study: 35278124
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg etifoxine
Study: 35278124
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg alprazolam
Study: 35710124
Drug: Guided internet
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet based cognitive behavioural therapy (CBT‐TF) with an eight step online programme, up to three hours of contact with a therapist, and four brief telephone calls or email contacts between sessions.
Study: 35710124
Drug: Guided internet
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet based cognitive behavioural therapy (CBT‐TF)
Study: 35710124
Drug: Individual face‐to‐face
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual face‐to‐face cognitive behavioural therapy (CBT‐TF)
Study: 34936159
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of traditional lecture and mobile application
Study: 35576534
Drug: Carbohydrate drink
Normalized name: Ensure Pre-Surgery Clear Carbohydrate Drink (Strawberry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate drink (CHO) group received 400 mL of a carbohydrate drink 2 to 3 hours before anesthesia
Study: 34919684
Drug: Con+BM (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Con+BM (control treatment consisting of placebo and basic care micronutrient mixture)
Study: 32894558
Drug: Myo-inositol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol (2 g), Alpha-Lactalbumin (50 mg), folic acid (200 µg) every morning for 6 months; Myo-inositol (600 mg), melatonin (1 mg), folic acid (200 µg) in the evening for 3 months before oocyte pick up; Myo-inositol (600 mg), folic acid (200 µg), melatonin (1 mg), vitamin D3 (50 µg) until the 12th week of gestation
Study: 32894558
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with 200 µg folic acid twice a day
Study: 36145188
Drug: Enzobiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzobiotic therapy (synbiotics and proteolytic enzymes) over 12 weeks
Study: 35265960
Drug: 24 g
Normalized name: glucose 24 g/31 g oral gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 g whole dragon fruit powder (33 mg betalains)
Study: 32811539
Drug: Goal-directed human
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed human albumin substitution aimed at a concentration > 30 g/l during surgery and postanesthesia care unit stay.
Study: 34958693
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 4-hexylresorcinol (4-HR) and niacinamide
Study: 33482797
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (5 ml of 2.5% sodium hypochlorite, followed by 5 ml of 17% EDTA and 5 ml of distilled water)
Study: 35965169
Drug: Remotely-administered resilience-
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remotely-administered resilience- and wisdom-focused intervention (6 once-a-week one-hour sessions)
Study: 35306660
Drug: Resistant dextrin
Normalized name: wheat dextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant dextrin (10 g day‐1 for 8 weeks)
Study: 616782991
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine pattern-based clinical nursing care